The estimated Net Worth of Jonathan C Fox is at least $53.4 Milión dollars as of 17 September 2020. Jonathan Fox owns over 5,767 units of Eidos Therapeutics Inc stock worth over $46,155,417 and over the last 9 years he sold EIDX stock worth over $7,277,265. In addition, he makes $0 as President a Chief Medical Officer at Eidos Therapeutics Inc.
Sign up
Jonathan Fox EIDX stock SEC Form 4 insiders trading
Jonathan has made over 22 trades of the Eidos Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 5,767 units of EIDX stock worth $289,273 on 17 September 2020.
The largest trade he's ever made was selling 15,000 units of Eidos Therapeutics Inc stock on 15 November 2019 worth over $729,750. On average, Jonathan trades about 5,643 units every 64 days since 2015. As of 17 September 2020 he still owns at least 377,673 units of Eidos Therapeutics Inc stock.
You can see the complete history of Jonathan Fox stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jonathan Fox biography
Dr. Jonathan C. Fox M.D. Ph.D. serves as President, Chief Medical Officer of the Company. Dr. Fox has served as the TA lead of cardiovascular and renal diseases at BridgeBio Pharma, Inc. since October 2016. Prior to that, from March 2013 to September 2016, Dr. Fox served as the chief medical officer of MyoKardia, Inc. and as a senior advisor from October 2016 to March 2017. He worked as a consultant at Nigel-Montgomery, LLC from August 2012 to March 2013 and held various senior positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca LP from 1998 to 2012. He was on the faculty of the University of Pennsylvania School of Medicine from 1993 to 2013. He currently holds an adjunct faculty position at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in medicine and pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases, and is a Fellow of the American College of Cardiology.
How old is Jonathan Fox?
Jonathan Fox is 62, he's been the President a Chief Medical Officer of Eidos Therapeutics Inc since 2016. There are 1 older and 6 younger executives at Eidos Therapeutics Inc. The oldest executive at Eidos Therapeutics Inc is Uma Sinha, 63, who is the Chief Scientific Officer, Director.
What's Jonathan Fox's mailing address?
Jonathan's mailing address filed with the SEC is C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2000, SAN FRANCISCO, CA, 94104.
Insiders trading at Eidos Therapeutics Inc
Over the last 6 years, insiders at Eidos Therapeutics Inc have traded over $18,169,563 worth of Eidos Therapeutics Inc stock and bought 30,345,136 units worth $349,599,962 . The most active insiders traders include Capital Management, L.P.Ra ..., Pharma, Inc. Bridge Bio a Rajeev M. Shah. On average, Eidos Therapeutics Inc executives and independent directors trade stock every 13 days with the average trade being worth of $52,576,942. The most recent stock trade was executed by Pharma, Inc. Bridge Bio on 26 January 2021, trading 14,428,836 units of EIDX stock currently worth $1,763,348,048.
What does Eidos Therapeutics Inc's logo look like?
Complete history of Jonathan Fox stock trades at MyoKardia a Eidos Therapeutics Inc
Eidos Therapeutics Inc executives and stock owners
Eidos Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Cameron Turtle,
Chief Business Officer -
William Lis,
Independent Director -
Uma Sinha,
Chief Scientific Officer, Director -
Ali Satvat,
Independent Director -
Neil Kumar,
Chief Executive Officer, Director -
Douglas Rohlen,
Independent Director -
Suzanne Hooper,
Independent Director -
Jonathan Fox,
President, Chief Medical Officer -
Franco Valle,
Senior Vice President, Finance -
Rajeev M. Shah,
Director -
Capital Management, L.P.Ra ...,
-
Christine Siu,
CFO and Secretary -
Hoyoung Huh,
Director -
Pharma, Inc. Bridge Bio,
10% owner -
Eric Aguiar,
Director